Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Kytril. Every FDA application for this active ingredient: 3 branded and 48 generic.
As of Nov 15, 2026, FDA lists 51 applications for Granisetron Hydrochloride (sold as Kytril), first approved Dec 29, 1993, with 5 new uses approved and 0 published complete response letters.
First approved: Dec 29, 1993
Applications: 51
New uses approved: 5
Complete response letters: 0
Medicare spending, 2025: $225K
First approved in the EU: Apr 20, 2012
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Granisetron HCL
Part B
$225K
-37%
15,324
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
GRANISETRON HCL 1 MG TABLET: $1.28 per unitGeneric · -15% in a year
Approvals in the EU (EMA)
First approved in the EU 220 months after the US. Centrally authorised medicines, matched by ingredient; see all EU approvals
KytrilDrugs with a new indication and a new dosage for the treatment of digestive symptoms (nausea and vomiting) after surgery. · Taiyo Pharma Co., Ltd. · Feb 25, 2022
Kytril Fine GranuleDrugs with a new additional indication for the treatment of gastrointestinal symptoms (nausea and vomiting) associated with radiation. · Chugai Pharmaceutical Co., Ltd. · Dec 22, 2011
Clinical Trials
2 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Roche
Hikma
Baxter Hlthcare Corp
Fresenius Kabi USA
Aurobindo Pharma USA
Sandoz
Taro
Eugia Pharma